Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
62nd European Renal Association (ERA) Congress 2025
June 6 - 7, 2025
Austria
Travere and National Kidney Foundation Collaboration
Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan
A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan Presented by Travere and ISN
March 11, 2025
Virtual
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston
World Congress of Nephrology (WCN) 2025
February 6 - 9, 2025
India
ASN Update
Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation